If you or someone who love has CANCER, I urge you to look into an amazing test called RGCC.

If you or someone you love has cancer, a physician recommends looking into a test called RGCC

Dr. Jesse Morse recently shared a post about a blood-based test called RGCC, and the summary is worth a slow read. The test isolates circulating tumor cells, sequences them, and returns a surprisingly practical set of results: a circulating tumor cell count (CTC), gene markers and aggressiveness, and specific percentages showing which chemotherapy agents are likely to work for that individual tumor.

It also checks more than 100 non-traditional options (things like vitamin C, curcumin, mistletoe), and you can add up to five extra compounds to test — people are already asking about ivermectin, fenbendazole, and mebendazole (yes, really). There are five different testing options depending on the goal, and a screening version exists too.

Practical details matter. The process is a simple blood draw, about three weeks of lab work, then a thorough report that the company will review with the treating oncologist or team. Dr. Morse notes that many oncologists haven’t heard of RGCC yet, but the company spends time explaining results to providers, which helps clinical teams use the data. Cost sits roughly in the $2,500 to $4,000 range, depending on the test.

He shared an example from a recent patient — a 31-year-old with stage 4 lung cancer — which illustrates how personalized data can change treatment thinking (this was not a paid endorsement; Dr. Morse says he has no affiliation and that many providers offer the test).

This kind of testing feels like a step toward targeted, measurement-driven care, moving away from guessing and toward calculation. It’s not a miracle cure, but it gives patients and doctors clearer options, and that clarity can shift decisions in meaningful ways. For those who want to explore further, see Dr. Jesse Morse’s post here: https://x.com/DrJesseMorse/status/2021959479911141545